Epigenetic dysregulation is increasingly appreciated as a hallmark of cancer, including
disease initiation, maintenance and therapy resistance. As a result, there have been …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at
numerous phases of the disease and progress under intense evolutionary pressures. Organ …

Abstract Androgen receptor-(AR-) indifference is a mechanism of resistance to hormonal
therapy in prostate cancer (PC). Here we demonstrate that ONECUT2 (OC2) activates …

In recent years, advancements in single-cell and spatial transcriptomics, which are highly
regarded developments in the current era, particularly the emerging integration of single-cell …

Androgen receptor (AR) drives prostate cancer (PCa) development and progression. AR
chromatin binding profiles are highly plastic and form recurrent programmatic changes that …

Background The prognostic and therapeutic implications of endothelial cells (ECs)
heterogeneity in prostate cancer (PCa) are poorly understood. Methods We investigated …

The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are
inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma …

Numerous research works have emphasized the critical role that circadian rhythm plays in
the tumor microenvironment (TME). The goal of clarifying chrono-pharmacological strategies …

Simple Summary African American (AA) men have 2.4 times higher mortality rate due to
prostate cancer than White men in the United States. Evidence implicates circadian rhythm …